Previous 10 | Next 10 |
Inari Medical ( NASDAQ: NARI ) is scheduled to announce Q4 earnings results on Monday, February 27th, after market close. The consensus EPS Estimate is -$0.17 and the consensus Revenue Estimate is $104.85M (+26.0% Y/Y). Over the last 3 months, EPS estimates have seen 2 upwar...
Summary After years of struggling to make real progress in its core atherectomy businesses, CSII is selling out to Abbott for $20/share in cash. Abbott is acquiring an established but likely slower-growing atherectomy business that has been disrupted by ShockWave's entry into the periph...
IRVINE, Calif., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its fourth quarter and ...
IRVINE, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that its management team will participate vi...
Wells Fargo said that based on early feedback from physicians, the recent launch of Penumbra's ( NYSE: PEN ) Lightning Flash mechanical thrombectomy system will boost growth for the company. The device is used for deep vein thrombosis (DVT) and pulmonary emboli ( PE ). Analyst...
Summary Penumbra has benefited from renewed enthusiasm around the company's neuro and peripheral thrombectomy platforms, and the company recently launched the Lightning Flash. Management is making a big bet on computer-aided aspiration for benefits like shorter procedure times and impro...
IRVINE, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that the first patient has been enrolled in D...
The shares of the medical device company Inari Medical ( NASDAQ: NARI ) jumped on Tuesday morning after reporting better-than-expected revenue for 2022 and setting its 2023 outlook ahead of the consensus. Citing preliminary unaudited financials, Inari ( NARI ) projected $107M ...
IRVINE, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced preliminary unaudited fourth quarter and ful...
Summary AngioDynamics posted a pretty clean fiscal second quarter that was a little better than the sell-side expected, and that seemed to drive a meaningful relief rally for the beaten-down shares. Lackluster results from AngioVac/AlphaVac bear watching, given that they're important gr...
News, Short Squeeze, Breakout and More Instantly...
IRVINE, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced that it will release its second quarter 2024...
Hagens Berman Encourages NARI Investors with Substantial Losses to Contact Firm Before July 12, 2024 Deadline San Francisco, California--(Newsfile Corp. - June 26, 2024) - Hagens Berman urges Inari Medical, Inc. (NASDAQ: NARI) investors who suffered substantial losses to submit your losses no...
2024-06-01 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...